Establishment of reference values in a healthy population and interpretation of serum PTH concentrations in hemodialyzed patients according to the KDIGO Guidelines using the Lumipulse® G whole PTH (3rd generation) assay

被引:10
作者
Cavalier, Etienne [1 ]
Salse, Margot [2 ]
Dupuy, Anne-Marie [2 ]
Bargnoux, Anne-Sophie [2 ]
Watar, Florence [1 ]
Souberbielle, Jean-Claude [3 ]
Delanaye, Pierre [4 ]
Cristol, Jean-Paul [2 ]
机构
[1] Univ Liege, CHU Liege, Dept Clin Chem, Liege, Belgium
[2] Lapeyronie Hosp, Dept Biochem & Hormonol, Montpellier, France
[3] Hop Necker Enfants Malad, Serv Explorat Fonct, Paris, France
[4] Univ Liege, CHU Liege, Dept Nephrol Dialysis & Transplantat, Liege, Belgium
关键词
Parathyroid hormone; PTH; Reference value; KDIGO; PARATHYROID-HORMONE; PRIMARY HYPERPARATHYROIDISM; DIALYSIS PATIENTS; PLASMA PTH; KITS;
D O I
10.1016/j.clinbiochem.2018.02.019
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: 3rd generation PTH assays only detect the bioactive 1-84 fragment. Since standardization is still lacking, each new PTH assay requires to establish reference values and to assess the impact in the medical care of the mineral and bone disorders in hemodialyzed patients. Methods: Using Fujirebio Lumipulse G wPTH assay, serum PTH levels were measured in a population of 439 healthy subjects from France and Belgium PTH levels were also determined in 119 hemodialyzed patients. These patients were classified according to the KDIGO recommendation. Results: Reference range was found to be 6.5 (90% CI: 6.0-7.0) - 41.8 (90% CI: 38.1-43.7). In hemodialysis patients, Passing-Bablock regression between 3rd generation PTH from Fujirebio and DiaSorin was DiaSorin = 1.01 xFujirebio-2.4 with a slope not different from 1.0(95% CI: 0.96-1.04) and a non-significant intercept, ranging from -6.0 to 0.1. Hemodialysis patients with a PTH concentration below 2-fold the Upper Limit of Normality (ULN), within the KDIGO range and upper 9-fold upper limit were respectively 33.6%, 54.6%, 11.8% (Fujirebio Lumipulse) and 36.1%, 51.3% and 12.6% (Diasorin Liaison). Conclusion: We determined a reference range with the 3rd generation PTH assay from Fujirebio. In a hemodialysis population, 3rd generation assays from Fujirebio and DiaSorin provide similar results. To the best of our knowledge, this is the first time that we can show similar PTH results obtained by 2 different 3rd generation PTH assays in healthy subjects and hemodialyzed patients without mathematically processing them.
引用
收藏
页码:119 / 122
页数:4
相关论文
共 16 条
[1]   Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop [J].
Bilezikian, John P. ;
Brandi, Maria Luisa ;
Eastell, Richard ;
Silverberg, Shonni J. ;
Udelsman, Robert ;
Marcocci, Claudio ;
Potts, John T., Jr. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (10) :3561-3569
[2]   Problems with the PTH assays [J].
Cavalier, Etienne ;
Delanaye, Pierre ;
Nyssen, Laurent ;
Souberbielle, Jean-Claude .
ANNALES D ENDOCRINOLOGIE, 2015, 76 (02) :128-133
[3]   Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations [J].
Cavalier, Etienne ;
Delanaye, Pierre ;
Lukas, Pierre ;
Carlisi, Agnes ;
Gadisseur, Romy ;
Souberbielle, Jean-Claude .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (08) :1137-1141
[4]  
Cavalier E, 2012, OSTEOPOROSIS INT, V23, pS360
[5]   Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values [J].
Cavalier, Etienne ;
Delanaye, Pierre ;
Vranken, Laura ;
Bekaert, Anne-Catherine ;
Carlisi, Agnes ;
Chapelle, Jean-Paul ;
Souberbielle, Jean-Claude .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (05) :1950-1956
[6]   The Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma [J].
Cavalier, Etienne ;
Daly, Adrian F. ;
Betea, Daniela ;
Pruteanu-Apetrii, Pamela Nicoleta ;
Delanaye, Pierre ;
Stubbs, Phil ;
Bradwell, Arthur R. ;
Chapelle, Jean-Paul ;
Beckers, Albert .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (08) :3745-3749
[7]  
Cavalier E, 2009, J BONE MINER RES, V24, P1638, DOI [10.1359/JBMR.090322, 10.1359/jbmr.090322]
[8]   Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19 [J].
D'Amour, P ;
Brossard, JH ;
Räkel, A ;
Rousseau, L ;
Albert, C ;
Cantor, T .
CLINICAL CHEMISTRY, 2005, 51 (01) :169-176
[9]   Performance Characteristics of Six Intact Parathyroid Hormone Assays [J].
La'ulu, Sonia L. ;
Roberts, William L. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (06) :930-938
[10]   Introduction and definition of CKD-MBD and the development of the guideline statements [J].
Moe, Sharon M. ;
Drueeke, Tilman B. ;
Block, Geoffrey A. ;
Cannata-Andia, Jorge B. ;
Elder, Grahame J. ;
Fukagawa, Masafumi ;
Jorgetti, Vanda ;
Ketteler, Markus ;
Langman, Craig B. ;
Levin, Adeera ;
MacLeod, Alison M. ;
McCann, Linda ;
McCullough, Peter A. ;
Ott, Susan M. ;
Wang, Angela Yee-Moon ;
Weisinger, Jose R. ;
Wheeler, David C. ;
Eckardt, Kai-Uwe ;
Kasiske, Bertram L. ;
Uhlig, Katrin ;
Moorthi, Ranjani ;
Earley, Amy ;
Persson, Rebecca .
KIDNEY INTERNATIONAL, 2009, 76 :S3-S130